Wierda W G, O'Brien S
UT MD Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA.
Expert Rev Anticancer Ther. 2001 Jun;1(1):73-83. doi: 10.1586/14737140.1.1.73.
Chronic lymphocytic leukemia (CLL) is typically an indolent B-cell malignancy, primarily affecting the aging population. Standard cytotoxic treatment with alkylating agents or purine analogs is very effective at inducing remission. However, curative treatment is not yet available. Immunotherapy is emerging as an exciting modality with significant potential to advance the treatment of this disease. This review discusses the different modalities of immunotherapy under investigation for the treatment of CLL. These modalities include passive immunotherapy with monoclonal antibodies against antigens on CLL B-cells including CD52 and CD20. Active immunotherapy by vaccination with genetically modified autologous leukemia cells is being evaluated in clinical trials. Allogeneic stem cell transplant for adoptive immunotherapy of CLL is yet another modality being investigated. While this modality may have limited application due to morbidity in older patients, it may result in improved survival and possibly cure. The use of immunotherapy in CLL is in the early stages of development. It is likely that this approach will significantly improve the treatment of CLL and possibly contribute to the cure of this disease.
慢性淋巴细胞白血病（CLL）通常是一种惰性B细胞恶性肿瘤，主要影响老年人群。使用烷化剂或嘌呤类似物进行的标准细胞毒性治疗在诱导缓解方面非常有效。然而，目前尚无治愈性治疗方法。免疫疗法正成为一种令人兴奋的治疗方式，具有推进该疾病治疗的巨大潜力。本综述讨论了正在研究的用于治疗CLL的不同免疫疗法方式。这些方式包括用针对CLL B细胞上抗原（包括CD52和CD20）的单克隆抗体进行被动免疫疗法。通过用基因改造的自体白血病细胞进行疫苗接种的主动免疫疗法正在临床试验中进行评估。用于CLL过继免疫疗法的异基因干细胞移植是正在研究的另一种方式。虽然由于老年患者的发病率，这种方式的应用可能有限，但它可能会提高生存率并有可能实现治愈。免疫疗法在CLL中的应用尚处于发展初期。这种方法很可能会显著改善CLL的治疗，并有可能有助于治愈该疾病。
